JWM
BMRN icon

JPL Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

JPL Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.6K Buy
+170
New +$9.91K ﹤0.01% 539
2025
Q4 		– Sell
-100
Closed -$5.42K – 246
2025
Q3 		$5.42K Buy
+100
New +$5.72K ﹤0.01% 651

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JPL Wealth Management's BMRN Position: Q1 2026 in Review

JPL Wealth Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 170 shares worth $9.6K. The stake represents ﹤0.01% of the portfolio and ranks #539 among its holdings. This is a return to the name: JPL Wealth Management previously reported a position in BMRN as recently as Q3 2025.

JPL Wealth Management first reported a position in BMRN in Q3 2025 and has held it in 2 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • JPL Wealth Management held 170 shares of BioMarin Pharmaceuticals worth $9.6K as of Q1 2026.
  • BioMarin Pharmaceuticals was a new JPL Wealth Management position in Q1 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of JPL Wealth Management's portfolio in Q1 2026, its #539 holding.
  • JPL Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on JPL Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.